ftc
parbradyphoto / iStockphoto.com
19 December 2018Big Pharma

FTC agrees to re-open Actavis and Watson merger decision

The Federal Trade Commission (FTC) has approved an application by pharmaceutical company Teva to re-open and modify its decision and order regarding the 2012 merger of Actavis and Watson Pharmaceuticals.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
4 January 2019   Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.
Generics
20 February 2019   Teva Pharmaceutical and the US Federal Trade Commission have reached a settlement to end their long-running battles over so called “pay-for-delay” agreements in the pharmaceutical industry.
Americas
18 March 2021   The Federal Trade Commission (FTC) is launching a new international working group in an “imperative” move to better analyse the impact of pharmaceutical mergers.

More on this story

Big Pharma
4 January 2019   Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.
Generics
20 February 2019   Teva Pharmaceutical and the US Federal Trade Commission have reached a settlement to end their long-running battles over so called “pay-for-delay” agreements in the pharmaceutical industry.
Americas
18 March 2021   The Federal Trade Commission (FTC) is launching a new international working group in an “imperative” move to better analyse the impact of pharmaceutical mergers.

More on this story

Big Pharma
4 January 2019   Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.
Generics
20 February 2019   Teva Pharmaceutical and the US Federal Trade Commission have reached a settlement to end their long-running battles over so called “pay-for-delay” agreements in the pharmaceutical industry.
Americas
18 March 2021   The Federal Trade Commission (FTC) is launching a new international working group in an “imperative” move to better analyse the impact of pharmaceutical mergers.